Bookmark and Share
BioAssay: AID 651990

Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP

Name: Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP. ..more
_
   
 Tested Compounds
 Tested Compounds
All(2)
 
 
Active(2)
 
 
 Tested Substances
 Tested Substances
All(2)
 
 
Active(2)
 
 
AID: 651990
Data Source: The Scripps Research Institute Molecular Screening Center (LYPLA1&2_INH_FLUO_ABPP_3XIC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2013-01-23
Hold-until Date: 2013-10-18
Modify Date: 2013-10-18

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 2
Related Experiments
Show more
AIDNameTypeProbeComment
2174Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).Screening depositor-specified cross reference: Primary screen (LYPLA1 inhibitors in singlicate)
2177Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).Screening depositor-specified cross reference: Primary screen (LYPLA2 inhibitors in singlicate)
2202Summary of probe development efforts to identify inhibitors of lysophospholipase 1 (LYPLA1).Summary2 depositor-specified cross reference: Summary (LYPLA1 inhibitors)
2203Summary of probe development efforts to identify inhibitors of lysophospholipase 2 (LYPLA2).Summary1 depositor-specified cross reference: Summary (LYPLA2 inhibitors)
2232Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2).Screening depositor-specified cross reference: Confirmation screen (LYPLA2 inhibitors in triplicate)
2233Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1).Screening depositor-specified cross reference: Confirmation screen (LYPLA1 inhibitors in triplicate)
493105Assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition of recombinant and endogenous enzymeOther depositor-specified cross reference: Confirmation screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493108Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: fluorescence-based cell-based inhibitionOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493109Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: LC-MS/MS assay to assess binding of compounds to active siteOther depositor-specified cross reference: Late stage LCMS assay (LYPLA1)
493110Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Gel-based Activity-Based Protein Profiling (ABPP) IC50 for LYPLA1 and LYPLA2Confirmatory depositor-specified cross reference: Late stage dose response (LYPLA1 and LYPLA2 inhibitors in triplicate)
493111Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493154Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Gel-based Activity-Based Protein Profiling (ABPP) IC50 for off-target ABHD11Confirmatory depositor-specified cross reference: Late stage dose response counterscreen (ABHD11 inhibitors in triplicate)
493161Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (T-cell cytotoxicity in quadruplicate)
504482Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based cell-based gel-based Activity-Based Protein Profiling (ABPP) IC50 for anti-target ABHD11Confirmatory depositor-specified cross reference: Late stage dose repsonse (ABHD11 inhibitors in triplicate)
504498Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: LC-MS/MS assay to assess binding of compounds to active site of anti-target ABHD11Other depositor-specified cross reference: Late stage MOA assay (ABDH11 LCMS)
504505Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based cell-based gel-based Activity-Based Protein Profiling (ABPP) percent inhibition for anti-target ABHD11Other depositor-specified cross reference: Late stage screen (ABHD11 inhibitors in singlicate, in situ)
504507Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) IC50 for anti-target ABHD11 Set 2Confirmatory depositor-specified cross reference: Late stage dose response (ABHD11 inhibitors in triplicate)
504510Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds set 2Confirmatory depositor-specified cross reference: Late stage dose repsonse counterscreen (T-cell cytotoxicity in quadruplicate)
504520Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) inhibition and selectivityOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
504522Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: LC-MS-based cell-based SILAC Activity-Based Protein Profiling (ABPP) for anti-target ABHD11Other depositor-specified cross reference: Late stage panel screen (ABHD11 SILAC ratio)
504892Late stage assay provider results from the probe development effort to identify inhibitors of ABHD11: Fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) inhibition of the human isoform of ABHD11Other depositor-specified cross reference: Late stage counterscreen (ABHD11 in singlicate)
652018Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2Other depositor-specified cross reference
652029Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibitionOther depositor-specified cross reference
652030Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther depositor-specified cross reference
743117Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition potency and selectivityOther depositor-specified cross reference
743118Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitroConfirmatory depositor-specified cross reference
743119Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in situConfirmatory depositor-specified cross reference
743127Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory depositor-specified cross reference
743132Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro in mouse brainConfirmatory depositor-specified cross reference
743133Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding modeOther depositor-specified cross reference
743134Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP assay to assess in vivo activityOther depositor-specified cross reference
743137 On Hold
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).Summary3 same project related to Summary assay
651978Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther same project related to Summary assay
651979Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther same project related to Summary assay
651980Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther same project related to Summary assay
651981Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther same project related to Summary assay
651985Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivoOther same project related to Summary assay
651986Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situOther same project related to Summary assay
651987Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding modeOther same project related to Summary assay
651988Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther same project related to Summary assay
651991Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory same project related to Summary assay
651998Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory same project related to Summary assay
652001Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory same project related to Summary assay
652003Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: fluorescence-based biochemical dose-response assayConfirmatory same project related to Summary assay
652004Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: fluorescence-based biochemical dose-response assayConfirmatory same project related to Summary assay
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).Summary3 same project related to Summary assay
651978Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther same project related to Summary assay
651979Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther same project related to Summary assay
651980Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther same project related to Summary assay
651981Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther same project related to Summary assay
651985Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivoOther same project related to Summary assay
651986Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situOther same project related to Summary assay
651987Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding modeOther same project related to Summary assay
651988Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther same project related to Summary assay
651991Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory same project related to Summary assay
651998Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory same project related to Summary assay
652001Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory same project related to Summary assay
652003Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: fluorescence-based biochemical dose-response assayConfirmatory same project related to Summary assay
652004Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: fluorescence-based biochemical dose-response assayConfirmatory same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: LYPLA1&2_INH_FLUO_ABPP_3XIC50

Name: Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP.

Description:

Protein palmitoylation is an essential post-translational modification necessary for trafficking and localization of regulatory proteins that play key roles in cell growth and signaling. Numerous proteins have been identified as targets of palmitoylation, including cytoskeletal proteins, kinases, receptors, and other proteins involved in various aspects of cellular signaling and homeostasis (1). Using a global chemo-proteomic method for the metabolic incorporation and identification of palmitoylated proteins, we were able to identify hundreds of palmitoylated proteins, revealing palmitoylation as a widespread post-translational modification (PTM) (2). Palmitoylation involves an acyl-thioester linkage to specific cysteines (3,4). Given the labile properties of thioesters, palmitoylation is potentially reversible and may be regulated in a manner analogous to other PTMs (e.g., phosphorylation). As such, identification of proteins responsible for the dynamic modulation of palmitoylation is paramount to understanding its patho/physiological roles. For example, multiple oncogenes, including HRAS and SRC, require palmitoylation for malignant transformation (5), suggesting protein palmitoyl thioesterases may have tumor suppressor activity required to repress aberrant growth signaling. More than a decade ago, the cytosolic serine hydrolase acyl-protein thioesterase 1 (APT1) was identified as an in vitro HRAS palmitoyl thioesterase (6). Initially classified as lysophospholipase 1 (LYPLA1) (7), the enzyme has since been demonstrated to have several hundred-fold higher activity as a protein thioesterase. While the in vitro data (6,8) provided an intriguing clue to its possible role in vivo, prior to our studies, little was known about the in vivo thioesterase activity of LYPLA1. Upon retroviral shRNA knockdown of LYPLA1, we found that HRAS was robustly hyper-palmitoylated, providing the first evidence that the endogenous enzyme is a functional protein palmitoyl thioesterase capable of regulating HRAS palmitoylation in mammalian cells. However, shRNA resulted in only an 80% reduction in LYPLA1 expression (unpublished). LYPLA2 (a.k.a. APT2) is 65% identical to LYPLA1, and also exhibits lysophospholipase activity in vitro, but its potential role as a thioesterase is unknown (9). shRNA knockdown studies of LYPLA2 revealed only partial knockdown of the enzyme, making substrate identification inconclusive (unpublished). A principle goal of post-genomic research is the determination of the molecular and cellular role of uncharacterized enzymes like LYPLA1 and LYPLA2. As such, selective inhibitors of LYPLA1 or LYPLA2 would greatly aid investigations into the biological function of these enzymes. Several inhibitors of LYPLA1 have been described (10,11), but none of these agents have proven capable of inhibiting LYPLA1 activity in cells, and no selective inhibitors of LYPLA2 have been reported to date. To comprehensively identify LYPLA1 and LYPLA2 substrates and functionally test the role of these enzymes in dynamic de-palmitoylation and tumorigenesis, development of high affinity inhibitors, capable of achieving temporal and more complete control over activity, is critical.

References:

1. Dekker, F.J., et al., Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol., 2010. 6(6): p. 449-56.
2. Duncan, J.A. and A.G. Gilman, A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS). J. Biol. Chem., 1998. 273(25): p. 15830-7.
3. Sugimoto, H., H. Hayashi, and S. Yamashita, Purification, cDNA cloning, and regulation of lysophospholipase from rat liver. J. Biol. Chem., 1996. 271(13): p. 7705-11.
4. Toyoda, T., H. Sugimoto, and S. Yamashita, Sequence, expression in Escherichia coli, and characterization of lysophospholipase II. Biochim. Biophys. Acta, 1999. 1437(2): p. 182-93.
5. Biel, M., et al., Synthesis and evaluation of acyl protein thioesterase 1 (APT1) inhibitors. Chemistry, 2006. 12(15): p. 4121-43.
6. Deck, P., et al., Development and biological evaluation of acyl protein thioesterase 1 (APT1) inhibitors. Angew. Chem. Int. Ed. Engl., 2005. 44(31): p. 4975-80.
7. Jessani, N., et al., Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. U. S. A., 2002. 99(16): p. 10335-40.
8. Leung, D., et al., Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol., 2003. 21(6): p. 687-91.
9. Bachovchin, D.A., et al., Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat. Biotechnol., 2009. 27(4): p. 387-94.
10. Forner, F., et al., Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver. Mol. Cell. Proteomics, 2006. 5(4): p. 608-19.
11. Schubert, C., The genomic basis of the Williams-Beuren syndrome. Cell. Mol. Life Sci., 2009. 66(7): p. 1178-97.

Keywords:

late stage, late stage AID, assay provider, powders, LYPLA1, lysophospholipase 1, LYPLA2, lysophospholipase 2, APT1, acyl-protein thioesterase 1, APT2, acyl-protein thioesterase 2, serine hydrolase, palmitoylation, protein palmitoylation, counterscreen, inhibitor, inhibition, activity-based protein profiling, ABPP, gel-based ABPP, HEK293T cells, fluorophosphonate peg rhodamine, FP-PEG-Rh, dose response, IC50, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Targets
PID§NameSubstancePanel TargetsDescriptionAdditional Information
ActiveInactive
1LYPLA111acyl-protein thioesterase 1 [Homo sapiens] [gi:5453722]
Taxonomy id: 9606
Gene id: 10434
2LYPLA211acyl-protein thioesterase 2 [Homo sapiens] [gi:9966764]
Taxonomy id: 9606
Gene id: 11313

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to determine IC50 values of powder samples of test compounds for inhibition of LYPLA1 and LYPLA2 in a complex proteomic lysate using a competitive activity-based proteomic profiling (ABPP) assay. In this assay, a complex proteome is incubated with test compound followed by reaction with the serine-hydrolase-specific rhodamine-conjugated fluorophosphonate (FP-PEG-Rh) activity-based probe. FP-PEG-Rh is similar to FP-Rh, but shows slower reaction kinetics, facilitating analysis of target inhibition by reversible compounds. The reaction products are separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner. The percentage activity remaining is determined by measuring the integrated optical density (IOD) of the bands. As designed, test compounds that act as LYPLA1 and/or LYPLA2 inhibitors will prevent enzyme-probe interactions, thereby decreasing the proportion of bound fluorescent probe, giving lower fluorescence intensity in the band in the gel. Percent inhibition is calculated relative to a DMSO (no compound) control.

Protocol Summary:
Soluble proteome (50 uL of 1 mg/ml in DPBS) of HEK293T cells was treated with varying concentrations of test compound (1 uL of a 50x stock in DMSO). Test compounds were incubated for 30 minutes at 37 C. FP-PEG-Rh (1 uL of 50x stock in DMSO) was added to a final concentration of 5 uM. The reaction was incubated for 30 minutes at 25C quenched with 2x SDS-PAGE loading buffer, separated by SDS-PAGE and visualized by in-gel fluorescent scanning. The percentage activity remaining was determined by measuring the integrated optical density of the LYPLA1 and LYPLA2 bands relative to a DMSO-only (no compound) control. IC50 values were determined from dose-response curves from three replicates in a 6-point dilution series from 0.001 uM to 3 uM.

%_Inhibition = ( 1 - ( IOD_Test_Compound - IOD_Low_Control ) / ( IOD_High_Control - IOD_Low_Control ) ) * 100

Where:

Test_Compound is defined as target or anti-target treated with test compound.
High_Control is defined as target or anti-target treated with DMSO only (no compound).
Low_Control is defined as background in a blank region of the gel.

For each test compound, percent inhibition was plotted against the log of the compound concentration. A three parameter equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc). The software-generated IC50 values are reported. In the event that the highest test concentration did not result in at least 50% inhibition, the IC50 value is reported as being greater than the highest test concentration.

PubChem Activity Outcome and Score:

The following applies to each panel in this assay:

Compounds with an IC50 less than or equal to 0.500 uM were considered active. Compounds with an IC50 greater than 0.500 uM were considered inactive.

Any compound with a percent activity value < 50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value >= 50% at any test concentration was assigned an activity score greater than zero.

Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

LYPLA1 Score: The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 0-0.

LYPLA2 Score: The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 0-0.

Overall Outcome and Score:

Compounds were considered active if they were active in only one of the panels. Compounds were considered inactive if they were inactive in both panels, or active in both panels.

The PubChem Activity Score is assigned a value of 100 for active compounds, and 0 for inactive compounds.

The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.

List of Reagents:

Soluble proteome of HEK293T cells (provided by the Assay Provider)
FP-PEG-Rh (provided by the Assay Provider)
DPBS (Cellgro 20-031-CV)
Comment
This assay was performed by the assay provider with powder samples of synthetic compounds.
Categorized Comment
Assay: Dictionary: Version: 0.1

Assay: CurveFit [1]: Equation: =[Baseline Response] + ( [Maximal Response] - [Baseline Response] ) / ( 1 + 10^( ( log( [Concentration] ) - [LogIC50] ) ) )

Assay: CurveFit [2]: Equation: =[Baseline Response] + ( [Maximal Response] - [Baseline Response] ) / ( 1 + 10^( ( log( [Concentration] ) - [LogIC50] ) ) )

Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Outcome [LYPLA1]One of Active, Inactive, or Not Tested1acyl-protein thioesterase 1 [Homo sapiens]Outcome
2Score [LYPLA1]BioAssay activity score1Integer
3Qualifier [LYPLA1]Qualifier identifies if the resultant IC50 was determined manually to be less than or greater than its listed IC50.1String
4IC50 [LYPLA1]*The concentration at which 50 percent inhibiton is observed; (IC50) shown in micromolar.1FloatμM
5LogIC50 [LYPLA1]log of IC501Float
6Baseline Response [LYPLA1]Adjustable baseline of the curve fit, minimal response value.1Float
7Maximal Response [LYPLA1]The maximal or asymptotic response above the baseline as concentration increases without bound.1Float
8Inhibition at 0.001 uM [LYPLA1] [1] (0.001μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.001 uM replicate [1]1Integer%
9Inhibition at 0.001 uM [LYPLA1] [2] (0.001μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.001 uM replicate [2]1Integer%
10Inhibition at 0.001 uM [LYPLA1] [3] (0.001μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.001 uM replicate [3]1Integer%
11Inhibition at 0.03 uM [LYPLA1] [1] (0.03μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.03 uM replicate [1]1Integer%
12Inhibition at 0.03 uM [LYPLA1] [2] (0.03μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.03 uM replicate [2]1Integer%
13Inhibition at 0.03 uM [LYPLA1] [3] (0.03μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.03 uM replicate [3]1Integer%
14Inhibition at 0.1 uM [LYPLA1] [1] (0.1μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.1 uM replicate [1]1Integer%
15Inhibition at 0.1 uM [LYPLA1] [2] (0.1μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.1 uM replicate [2]1Integer%
16Inhibition at 0.1 uM [LYPLA1] [3] (0.1μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.1 uM replicate [3]1Integer%
17Inhibition at 0.3 uM [LYPLA1] [1] (0.3μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.3 uM replicate [1]1Integer%
18Inhibition at 0.3 uM [LYPLA1] [2] (0.3μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.3 uM replicate [2]1Integer%
19Inhibition at 0.3 uM [LYPLA1] [3] (0.3μM**)The value of percent inhibition of endogenous human LYPLA1 at 0.3 uM replicate [3]1Integer%
20Inhibition at 1 uM [LYPLA1] [1] (1μM**)The value of percent inhibition of endogenous human LYPLA1 at 1 uM replicate [1]1Integer%
21Inhibition at 1 uM [LYPLA1] [2] (1μM**)The value of percent inhibition of endogenous human LYPLA1 at 1 uM replicate [2]1Integer%
22Inhibition at 1 uM [LYPLA1] [3] (1μM**)The value of percent inhibition of endogenous human LYPLA1 at 1 uM replicate [3]1Integer%
23Inhibition at 3 uM [LYPLA1] [1] (3μM**)The value of percent inhibition of endogenous human LYPLA1 at 3 uM replicate [1]1Integer%
24Inhibition at 3 uM [LYPLA1] [2] (3μM**)The value of percent inhibition of endogenous human LYPLA1 at 3 uM replicate [2]1Integer%
25Inhibition at 3 uM [LYPLA1] [3] (3μM**)The value of percent inhibition of endogenous human LYPLA1 at 3 uM replicate [3]1Integer%
26Outcome [LYPLA2]One of Active, Inactive, or Not Tested2acyl-protein thioesterase 2 [Homo sapiens]Outcome
27Score [LYPLA2]BioAssay activity score2Integer
28Qualifier [LYPLA2]Qualifier identifies if the resultant IC50 was determined manually to be less than or greater than its listed IC50.2String
29IC50 [LYPLA2]*The concentration at which 50 percent inhibiton is observed; (IC50) shown in micromolar.2FloatμM
30LogIC50 [LYPLA2]log of IC502Float
31Baseline Response [LYPLA2]Adjustable baseline of the curve fit, minimal response value.2Float
32Maximal Response [LYPLA2]The maximal or asymptotic response above the baseline as concentration increases without bound.2Float
33Inhibition at 0.001 uM [LYPLA2] [1] (0.001μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.001 uM replicate [1]2Integer%
34Inhibition at 0.001 uM [LYPLA2] [2] (0.001μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.001 uM replicate [2]2Integer%
35Inhibition at 0.001 uM [LYPLA2] [3] (0.001μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.001 uM replicate [3]2Integer%
36Inhibition at 0.03 uM [LYPLA2] [1] (0.03μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.03 uM replicate [1]2Integer%
37Inhibition at 0.03 uM [LYPLA2] [2] (0.03μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.03 uM replicate [2]2Integer%
38Inhibition at 0.03 uM [LYPLA2] [3] (0.03μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.03 uM replicate [3]2Integer%
39Inhibition at 0.1 uM [LYPLA2] [1] (0.1μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.1 uM replicate [1]2Integer%
40Inhibition at 0.1 uM [LYPLA2] [2] (0.1μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.1 uM replicate [2]2Integer%
41Inhibition at 0.1 uM [LYPLA2] [3] (0.1μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.1 uM replicate [3]2Integer%
42Inhibition at 0.3 uM [LYPLA2] [1] (0.3μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.3 uM replicate [1]2Integer%
43Inhibition at 0.3 uM [LYPLA2] [2] (0.3μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.3 uM replicate [2]2Integer%
44Inhibition at 0.3 uM [LYPLA2] [3] (0.3μM**)The value of percent inhibition of endogenous human LYPLA2 at 0.3 uM replicate [3]2Integer%
45Inhibition at 1 uM [LYPLA2] [1] (1μM**)The value of percent inhibition of endogenous human LYPLA2 at 1 uM replicate [1]2Integer%
46Inhibition at 1 uM [LYPLA2] [2] (1μM**)The value of percent inhibition of endogenous human LYPLA2 at 1 uM replicate [2]2Integer%
47Inhibition at 1 uM [LYPLA2] [3] (1μM**)The value of percent inhibition of endogenous human LYPLA2 at 1 uM replicate [3]2Integer%
48Inhibition at 3 uM [LYPLA2] [1] (3μM**)The value of percent inhibition of endogenous human LYPLA2 at 3 uM replicate [1]2Integer%
49Inhibition at 3 uM [LYPLA2] [2] (3μM**)The value of percent inhibition of endogenous human LYPLA2 at 3 uM replicate [2]2Integer%
50Inhibition at 3 uM [LYPLA2] [3] (3μM**)The value of percent inhibition of endogenous human LYPLA2 at 3 uM replicate [3]2Integer%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 CA132630

Classification
PageFrom: